Xvivo Perfusion AB
STO:XVIVO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
256.5
539
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one XVIVO stock under the Base Case scenario is 251.13 SEK. Compared to the current market price of 451.5 SEK, Xvivo Perfusion AB is Overvalued by 44%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Xvivo Perfusion AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for XVIVO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Xvivo Perfusion AB
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Xvivo Perfusion AB
Balance Sheet Decomposition
Xvivo Perfusion AB
Current Assets | 828.1m |
Cash & Short-Term Investments | 450m |
Receivables | 188m |
Other Current Assets | 190.1m |
Non-Current Assets | 1.5B |
Long-Term Investments | 42.8m |
PP&E | 121.7m |
Intangibles | 1.3B |
Current Liabilities | 150.8m |
Other Current Liabilities | 150.8m |
Non-Current Liabilities | 44.2m |
Long-Term Debt | 14.7m |
Other Non-Current Liabilities | 29.5m |
Earnings Waterfall
Xvivo Perfusion AB
Revenue
|
750.6m
SEK
|
Cost of Revenue
|
-192.1m
SEK
|
Gross Profit
|
558.5m
SEK
|
Operating Expenses
|
-501.7m
SEK
|
Operating Income
|
56.8m
SEK
|
Other Expenses
|
147.5m
SEK
|
Net Income
|
204.3m
SEK
|
Free Cash Flow Analysis
Xvivo Perfusion AB
SEK | |
Free Cash Flow | SEK |
XVIVO Profitability Score
Profitability Due Diligence
Xvivo Perfusion AB's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Xvivo Perfusion AB's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
XVIVO Solvency Score
Solvency Due Diligence
Xvivo Perfusion AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Xvivo Perfusion AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XVIVO Price Targets Summary
Xvivo Perfusion AB
According to Wall Street analysts, the average 1-year price target for XVIVO is 544.48 SEK with a low forecast of 484.8 SEK and a high forecast of 613.2 SEK.
Dividends
Current shareholder yield for XVIVO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
XVIVO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Xvivo Perfusion AB is a medical technology company. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 92 full-time employees. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.
Contact
IPO
Employees
Officers
The intrinsic value of one XVIVO stock under the Base Case scenario is 251.13 SEK.
Compared to the current market price of 451.5 SEK, Xvivo Perfusion AB is Overvalued by 44%.